Next-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA

Download All
Experts discuss how they incorporate BCMA-targeted agents into the treatment of patients with MM and manage toxicities associated with these agents. This program features ClinicalThought commentaries, downloadable slides, and an on-demand webcast from a live webinar.
Sagar Lonial, MD
Program Director
Suzanne Lentzsch, MD, PhD
Sagar Lonial, MD
Thomas G. Martin, MD

ClinicalThought

How I am using currently approved anti-BCMA agents as a part of the treatment plan for patients with R/R MM.

Sagar Lonial, MD Released: September 9, 2021

Experts answer frequently asked questions on the management of relapsed or refractory multiple myeloma with BCMA-targeted agents.

Sagar Lonial, MD
Program Director
Suzanne Lentzsch, MD, PhD Thomas G. Martin, MD
Released: October 29, 2021

Downloadable Slidesets

Download this slideset based on the content from a live stream CCO webinar from Sagar Lonial, MD, on optimal use of anti-BMCA antibody–drug conjugates for patients with relapsed/refractory multiple myeloma.

Sagar Lonial, MD Released: September 10, 2021

Download this slideset based on the content from a live stream CCO webinar from Thomas G. Martin, MD, on how to integrate CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.

Thomas G. Martin, MD Released: September 10, 2021

Download this slideset based on the content from a live stream CCO webinar from Suzanne Lentzsch, MD, PhD, on the latest data on BCMA x CD3 bispecific molecules for patients with relapsed/refractory multiple myeloma.

Suzanne Lentzsch, MD, PhD Released: September 10, 2021

Gain key clinical insights fast, with this short slideset from CCO on key considerations for optimal use of anti-BMCA therapy for patients with relapsed/refractory multiple myeloma.

Suzanne Lentzsch, MD, PhD Sagar Lonial, MD Thomas G. Martin, MD Released: October 5, 2021

On-Demand Webcast

On-demand webcast of a CCO live webinar on the use of BCMA-targeted agents in relapsed/refractory multiple myeloma.

Sagar Lonial, MD
Program Director
Suzanne Lentzsch, MD, PhD Thomas G. Martin, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: October 15, 2021 Expired: October 14, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings